May 13, 2024 02:55 PM EDT
R&D
Coronavirus

Sh­iono­gi miss­es pri­ma­ry end­point in Phase 3 for Covid-19 an­tivi­ral

Katherine Lewin

News Reporter

Sh­iono­gi’s once-dai­ly Covid-19 an­tivi­ral en­sitrelvir missed the pri­ma­ry end­point in a Phase 3 study, two months af­ter scor­ing full ap­proval in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

House’s promi­nent Chi­na crit­ic Jim Mc­Gov­ern leads op­po­si­tion to Biose­cure Act: ‘I would pre­fer to go back to the ...

Benev­o­len­tAI CEO is out af­ter less than a year on the job

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times